The past, present and future of renin–angiotensin aldosterone system inhibition

Mentz, R. J. et al. (2013) The past, present and future of renin–angiotensin aldosterone system inhibition. International Journal of Cardiology, 167(5), pp. 1677-1687. (doi: 10.1016/j.ijcard.2012.10.007) (PMID:23121914) (PMCID:PMC4145865)

Full text not currently available from Enlighten.


The renin–angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction. This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies. Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.

Item Type:Articles
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Mentz, R. J., Bakris, G. L., Waeber, B., McMurray, J. J.V., Gheorghiade, M., Ruilope, L. M., Maggioni, A. P., Swedberg, K., Piña, I. L., Fiuzat, M., O'Connor, C. M., Zannad, F., and Pitt, B.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:International Journal of Cardiology
Publisher:Elsevier Science B.V., Amsterdam.
ISSN (Online):1874-1754

University Staff: Request a correction | Enlighten Editors: Update this record